Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rheumatology
•
Langerhans Cell Histiocytosis
•
Hematology
•
General Rheumatology
•
Dermatology
•
Pediatric Rheumatology
•
Oncology
How do you approach evaluation of Langerhans cell histiocytosis?
What clinical features should raise suspicion for this diagnosis?
Related Questions
When would you consider use of emapalumab for HLH/MAS?
How do you approach management autoimmune lymphoproliferative syndrome (ALPS) complicated by HLH?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Is there any benefit to checking serum viscosity in patients with autoimmune disease and headaches/migraines to see if aspirin or clopidogrel may be beneficial?
How do you approach patients who identify so strongly with being sick or with a particular diagnostic label that it makes up a significant portion of their identity?
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
How would you approach escalation of therapy in an adult patient with refractory Still’s disease and associated MAS/HLH (ferritin >100,000, transaminitis, DIC) despite high-dose steroids, high-dose anakinra, tocilizumab, and ruxolitinib?
Do you consider co-prescribing hormone therapy and anticoagulation in a patient with prior DVT and uncontrollable VSM uncontrolled by non-hormonal therapies?
Do you check the Duffy-null phenotype before starting azathioprine and in which patients?
How often do you recommend ophthalmologic screening exams for patients with sarcoidosis?